CDNA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

29.425

Open

29.360

VWAP

28.64

Vol

626.13K

Mkt Cap

1.46B

Low

28.190

Amount

17.93M

EV/EBITDA(TTM)

153.89

Total Shares

51.66M

EV

1.31B

EV/OCF(TTM)

18.01

P/S(TTM)

3.74

CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Show More

Events Timeline

(ET)

2026-06-16

16:30:00

CareDx Publishes Kidney Transplant Study Analysis

2026-06-01 (ET)

2026-06-01

09:40:00

U.S. Supreme Court Denies CareDx Appeal

2026-05-11 (ET)

2026-05-11

16:20:00

CareDx Dismisses Qui Tam Action Against Company

2026-04-28 (ET)

2026-04-28

16:20:00

Transplant Company Enters Definitive Agreement to Acquire Naveris for $160 Million

2026-04-28

16:20:00

CareDx Reports Q1 Revenue of $118M

2026-04-28

16:20:00

Company Expects 2026 Adjusted EBITDA of $43M to $57M

2026-04-20 (ET)

2026-04-20

07:30:00

CareDx Introduces AlloSeq Nano Genotyping Solution

News

NASDAQ.COM

07-02NASDAQ.COM

CareDx Completes Acquisition of Naveris

Yahoo Finance

07-01Yahoo Finance

Eurobio Scientific Completes Acquisition of CareDx's Transplant Lab Product Division

NASDAQ.COM

06-22NASDAQ.COM

CareDx CEO Sells Shares Amid Scheduled Transactions

Fool

CareDx CEO Sells 17K Shares Amid Scheduled Transactions

Yahoo Finance

06-22Yahoo Finance

CareDx CEO Sells 17K Shares Amid Scheduled Transactions

NASDAQ.COM

06-19NASDAQ.COM

CareDx Stock Surpasses Analyst Target Price

4 Analyst Rating

Wall Street analysts forecast CDNA stock price to rise

1 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

BTIG

Buy

maintain

$26 -> $28

AI Analysis

2026-04-29

Reason

BTIG

Price Target

$26 -> $28

AI Analysis

2026-04-29

maintain

Buy

Reason

BTIG raised the firm's price target on CareDx to $28 from $26 and keeps a Buy rating on the shares. The company has announced many positive updates on its Q1 call, and the biggest was its deal to acquire Naveris, a privately held MRD company, for up to $260M, the analyst tells investors in a research note. BTIG adds it expects CareDx to exceed its 2027 LR revenue target of $500M, driven by outperformance of its core transplant business and exchanging its low-margin, non-core products business for a much faster-growing, higher-margin new MRD business.

BTIG

Buy

maintain

$25 -> $26

2026-02-25

Reason

BTIG

Price Target

$25 -> $26

2026-02-25

maintain

Buy

Reason

BTIG raised the firm's price target on CareDx to $26 from $25 and keeps a Buy rating on the shares. The company delivered a good Q4 and initiated a 2026 revenue guidance above the Street estimates, albeit the guide was understandably wide in its range, the analyst tells investors in a research note. The firm adds however that while many investors are waiting on the sidelines until a final resolution occurs with CMS, BTIG believes that the stock is cheap regardless of that outcome.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CDNA

Unlock Now

Valuation Metrics

The current forward P/E ratio for CareDx Inc (CDNA.O) is 94.34, compared to its 5-year average forward P/E of 13.13. For a more detailed relative valuation and DCF analysis to assess CareDx Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

13.13

Current PE

94.34

Overvalued PE

124.00

Undervalued PE

-97.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

12.95

Current EV/EBITDA

51.66

Overvalued EV/EBITDA

120.88

Undervalued EV/EBITDA

-94.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.56

Current PS

3.13

Overvalued PS

6.27

Undervalued PS

0.85

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

for a fast profit in a day or two

Intellectia · 11 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, PharmaceuticalsMoving Average Relationship: PriceAboveMA5One Day Rise Prob: >= 55One Day Predict Return: 2.0% - 20.0%Monthly Average Dollar Volume: >= 200,000

Ticker

Name

Market Cap$

Artiva Biotherapeutics Inc

299.32M

CareDx Inc

1.15B

Enveric Biosciences Inc

4.44M

Mink Therapeutics Inc

70.17M

Altimmune Inc

456.67M

Novavax Inc

1.41B

en cuál está acciones puedo ganar dinero

Intellectia · 17 candidates

Revenue 5yr Cagr: >= 10Debt Equity: <= 0.500Weekly Average Turnover: >= 1,000,000Return On Equity: >= 15.0%

Ticker

Name

Market Cap$

Pegasystems Inc

8.13B

Cal-Maine Foods Inc

3.79B

Lululemon Athletica Inc

22.27B

Niagen Bioscience Inc

494.80M

Argan Inc

5.51B

Texas Roadhouse Inc

12.66B

find me the next stock like opgn

Intellectia · 31 candidates

Quarter Revenue Yoy Growth: >= 20.0%Market Cap Category: small, microBeta: HighRiskWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Monte Rosa Therapeutics Inc

1.85B

Syndax Pharmaceuticals Inc

1.78B

Harrow Inc

1.75B

Tango Therapeutics Inc

1.68B

Stoke Therapeutics Inc

1.68B

Intellia Therapeutics Inc

1.63B

Strong fundamental but undervalued

Intellectia · 9 candidates

Market Cap: >= 1000.00MGross Margin: >= 35.00Debt Equity: <= 0.800Pe Ttm: <= 20Return On Equity: >= 12.0%

Ticker

Name

Market Cap$

Lululemon Athletica Inc

22.27B

SEI Investments Co

10.53B

Nice Ltd

6.98B

Urban Outfitters Inc

6.44B

Abercrombie & Fitch Co

4.54B

Buckle Inc

2.83B

look at small cap companies

Intellectia · 7 candidates

Market Cap: 300.00M - 2.00BDebt Equity: <= 1Weekly Average Turnover: >= 1,000,000Return On Equity: >= 10.0%Annual Revenue Yoy Growth: >= 10.0%

Ticker

Name

Market Cap$

GigaCloud Technology Inc

1.47B

CareDx Inc

1.07B

Esquire Financial Holdings Inc

939.55M

Insteel Industries Inc

642.99M

Ibotta Inc

642.24M

Niagen Bioscience Inc

494.80M

Whales Holding CDNA

Portolan Capital Management, LLC

Deerfield Management Company, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is CareDx Inc (CDNA) stock price today?

The current price of CDNA is 28.31 USD — it has decreased -2.58

What is CareDx Inc (CDNA)'s business?

CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

What is the price predicton of CDNA Stock?

Wall Street analysts forecast CDNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CareDx Inc (CDNA)'s revenue for the last quarter?

CareDx Inc revenue for the last quarter amounts to 117.70M USD, increased 38.99

What is CareDx Inc (CDNA)'s earnings per share (EPS) for the last quarter?

CareDx Inc. EPS for the last quarter amounts to 0.05 USD, decreased -126.32

How many employees does CareDx Inc (CDNA). have?

CareDx Inc (CDNA) has 761 emplpoyees as of July 08 2026.

What is CareDx Inc (CDNA) market cap?

Today CDNA has the market capitalization of 1.46B USD.